These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16722838)

  • 1. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?
    Knights KM; Mangoni AA; Miners JO
    Br J Clin Pharmacol; 2006 Jun; 61(6):738-40. PubMed ID: 16722838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
    Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
    Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
    Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity of NSAIDs for COX-2 and cardiovascular outcome.
    Maxwell SR; Payne RA; Murray GD; Webb DJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):243-5. PubMed ID: 16842401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
    Jukić A; Kaliterna DM; Radić M
    Reumatizam; 2010; 57(1):26-8. PubMed ID: 20941937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
    Maillard M; Burnier M
    Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal adverse effects of nonsteroidal anti-inflammatory drugs.
    Harirforoosh S; Jamali F
    Expert Opin Drug Saf; 2009 Nov; 8(6):669-81. PubMed ID: 19832117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
    Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.